This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Assessing Ocular Surface Changes After Changing Glaucoma Medications

This study has been completed.
Information provided by (Responsible Party):
University of Colorado, Denver Identifier:
First received: November 2, 2007
Last updated: January 26, 2017
Last verified: January 2017
Hypothesis: Changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.

Glaucoma Monotherapy With Xalatan From 1 to 18 Months Ocular Surface Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Assessing Changes at the Ocular Surface Following the Switch From Xalatan to Travatan Z.

Resource links provided by NLM:

Further study details as provided by University of Colorado, Denver:

Primary Outcome Measures:
  • Change in Signs and Symptoms of Ocular Surface Disease [ Time Frame: 6 months ]

Enrollment: 22
Study Start Date: November 2007
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Detailed Description:
Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to Travatan Z. Test results will be recorded at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the Ocular Surface Disease Index.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients will be selected from the ophthalmology clinic of the principal investigator

Inclusion Criteria:

  • on Xalatan monotherapy from 1 to 18 months
  • 18 years of age or older
  • has been diagnosed with ocular surface disease

Exclusion Criteria:

  • special populations such as children, pregnant females, prisoners, etc.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00554411

United States, Colorado
Rocky Mountain Lions Eye Institute
Aurora, Colorado, United States, 80045-0510
Sponsors and Collaborators
University of Colorado, Denver
Principal Investigator: Malik Y Kahook, M.D. Rocky mountain Lions Eye Institute
  More Information

Responsible Party: University of Colorado, Denver Identifier: NCT00554411     History of Changes
Other Study ID Numbers: 07-0757
Study First Received: November 2, 2007
Last Updated: January 26, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by University of Colorado, Denver:
Travatan Z
tear film break up time

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Antihypertensive Agents processed this record on August 17, 2017